Clinical Trial Update: A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

View source ↗

Summary

This document reports the completion of a prospective observational study evaluating targeted therapy for unresectable or metastatic BRAFV600E-mutant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BRAFV600E targeted therapy

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: Melanoma (Skin), Metastatic Melanoma | Status: COMPLETED